Insmed Inc (INSM)vsSangamo Therapeutics Inc (SGMO)
INSM
Insmed Inc
$148.31
+6.59%
HEALTHCARE · Cap: $29.99B
SGMO
Sangamo Therapeutics Inc
$0.35
+4.93%
HEALTHCARE · Cap: $123.29M
Smart Verdict
WallStSmart Research — data-driven comparison
Insmed Inc generates 1745% more annual revenue ($606.42M vs $32.88M). SGMO leads profitability with a 0.0% profit margin vs -2.1%. INSM earns a higher WallStSmart Score of 39/100 (F).
INSM
Hold39
out of 100
Grade: F
SGMO
Avoid19
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
No standout strengths identified
Areas to Watch
1.5% revenue growth
0.0% earnings growth
Trading at 43.0x book value
ROE of -2.5% — below average capital efficiency
Trading at 17.6x book value
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : INSM
PEG of 1.09 suggests the stock is reasonably priced for its growth.
Bull Case : SGMO
SGMO has a balanced fundamental profile.
Bear Case : INSM
The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.
Bear Case : SGMO
The primary concerns for SGMO are Price/Book, EPS Growth, Market Cap.
Key Dynamics to Monitor
INSM profiles as a turnaround stock while SGMO is a value play — different risk/reward profiles.
SGMO carries more volatility with a beta of 1.32 — expect wider price swings.
INSM is growing revenue faster at 1.5% — sustainability is the question.
SGMO generates stronger free cash flow (-29M), providing more financial flexibility.
Bottom Line
INSM scores higher overall (39/100 vs 19/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Insmed Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.
Sangamo Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Sangamo Therapeutics, Inc., a clinical-stage biotechnology company, focuses on translating science into genomic drugs that transform the lives of patients using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. The company is headquartered in Brisbane, California.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?